These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 34952479)

  • 1. T cell immune awakening in response to immunotherapy is age-dependent.
    Salih Z; Banyard A; Tweedy J; Galvani E; Middlehurst P; Mills S; Weightman J; Gupta A; Lorigan PC; Zhou C; Dhomen N; Valpione S; Marais R
    Eur J Cancer; 2022 Feb; 162():11-21. PubMed ID: 34952479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TCR Repertoire Diversity of Peripheral PD-1
    Han J; Duan J; Bai H; Wang Y; Wan R; Wang X; Chen S; Tian Y; Wang D; Fei K; Yao Z; Wang S; Lu Z; Wang Z; Wang J
    Cancer Immunol Res; 2020 Jan; 8(1):146-154. PubMed ID: 31719056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune-awakening revealed by peripheral T cell dynamics after one cycle of immunotherapy.
    Valpione S; Galvani E; Tweedy J; Mundra PA; Banyard A; Middlehurst P; Barry J; Mills S; Salih Z; Weightman J; Gupta A; Gremel G; Baenke F; Dhomen N; Lorigan PC; Marais R
    Nat Cancer; 2020 Feb; 1(2):210-221. PubMed ID: 32110781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distinct Biomarker Profiles and TCR Sequence Diversity Characterize the Response to PD-L1 Blockade in a Mouse Melanoma Model.
    El Meskini R; Atkinson D; Kulaga A; Abdelmaksoud A; Gumprecht M; Pate N; Hayes S; Oberst M; Kaplan IM; Raber P; Van Dyke T; Sharan SK; Hollingsworth R; Day CP; Merlino G; Weaver Ohler Z
    Mol Cancer Res; 2021 Aug; 19(8):1422-1436. PubMed ID: 33888600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peripheral CD8
    Fairfax BP; Taylor CA; Watson RA; Nassiri I; Danielli S; Fang H; Mahé EA; Cooper R; Woodcock V; Traill Z; Al-Mossawi MH; Knight JC; Klenerman P; Payne M; Middleton MR
    Nat Med; 2020 Feb; 26(2):193-199. PubMed ID: 32042196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early memory differentiation and cell death resistance in T cells predicts melanoma response to sequential anti-CTLA4 and anti-PD1 immunotherapy.
    Vanmeerbeek I; Borras DM; Sprooten J; Bechter O; Tejpar S; Garg AD
    Genes Immun; 2021 Jun; 22(2):108-119. PubMed ID: 34079092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tissue-resident memory T cells from a metastatic vaginal melanoma patient are tumor-responsive T cells and increase after anti-PD-1 treatment.
    Pizzolla A; Keam SP; Vergara IA; Caramia F; Thio N; Wang M; Kocovski N; Tantalo D; Jabbari J; Au-Yeung G; Sandhu S; Gyorki DE; Weppler A; Perdicchio M; McArthur GA; Papenfuss AT; Neeson PJ
    J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35550554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clonality of CD4
    Arakawa A; Vollmer S; Tietze J; Galinski A; Heppt MV; Bürdek M; Berking C; Prinz JC
    Front Immunol; 2019; 10():1336. PubMed ID: 31275310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD4
    Xiao M; Xie L; Cao G; Lei S; Wang P; Wei Z; Luo Y; Fang J; Yang X; Huang Q; Xu L; Guo J; Wen S; Wang Z; Wu Q; Tang J; Wang L; Chen X; Chen C; Zhang Y; Yao W; Ye J; He R; Huang J; Ye L
    J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35580929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular patterns of resistance to immune checkpoint blockade in melanoma.
    Lauss M; Phung B; Borch TH; Harbst K; Kaminska K; Ebbesson A; Hedenfalk I; Yuan J; Nielsen K; Ingvar C; Carneiro A; Isaksson K; Pietras K; Svane IM; Donia M; Jönsson G
    Nat Commun; 2024 Apr; 15(1):3075. PubMed ID: 38594286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Checkpoint blockade immunotherapy enhances the frequency and effector function of murine tumor-infiltrating T cells but does not alter TCRβ diversity.
    Kuehm LM; Wolf K; Zahour J; DiPaolo RJ; Teague RM
    Cancer Immunol Immunother; 2019 Jul; 68(7):1095-1106. PubMed ID: 31104075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dynamics of Melanoma-Associated Epitope-Specific CD8+ T Cells in the Blood Correlate With Clinical Outcome Under PD-1 Blockade.
    Gaißler A; Meldgaard TS; Heeke C; Babaei S; Tvingsholm SA; Bochem J; Spreuer J; Amaral T; Wagner NB; Klein R; Meier F; Garbe C; Eigentler TK; Pawelec G; Claassen M; Weide B; Hadrup SR; Wistuba-Hamprecht K
    Front Immunol; 2022; 13():906352. PubMed ID: 35874702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fibroblast growth factor receptor 3 alterations and response to immune checkpoint inhibition in metastatic urothelial cancer: a real world experience.
    Rose TL; Weir WH; Mayhew GM; Shibata Y; Eulitt P; Uronis JM; Zhou M; Nielsen M; Smith AB; Woods M; Hayward MC; Salazar AH; Milowsky MI; Wobker SE; McGinty K; Millburn MV; Eisner JR; Kim WY
    Br J Cancer; 2021 Oct; 125(9):1251-1260. PubMed ID: 34294892
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PD-L1 Checkpoint Inhibition Narrows the Antigen-Specific T Cell Receptor Repertoire in Chronic Lymphocytic Choriomeningitis Virus Infection.
    Klein S; Ghersi D; Manns MP; Prinz I; Cornberg M; Kraft ARM
    J Virol; 2020 Aug; 94(18):. PubMed ID: 32641478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Time-spatial analysis of T cell receptor repertoire in esophageal squamous cell carcinoma patients treated with combined radiotherapy and PD-1 blockade.
    Yan C; Ma X; Guo Z; Wei X; Han D; Zhang T; Chen X; Cao F; Dong J; Zhao G; Gao X; Wang T; Jiang Y; Wang P; Pang Q; Zhang W
    Oncoimmunology; 2022; 11(1):2025668. PubMed ID: 35036077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination immunotherapy induces distinct T-cell repertoire responses when administered to patients with different malignancies.
    Cham J; Zhang L; Kwek S; Paciorek A; He T; Fong G; Oh DY; Fong L
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32376721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early disappearance of tumor antigen-reactive T cells from peripheral blood correlates with superior clinical outcomes in melanoma under anti-PD-1 therapy.
    Bochem J; Zelba H; Spreuer J; Amaral T; Wagner NB; Gaissler A; Pop OT; Thiel K; Yurttas C; Soffel D; Forchhammer S; Sinnberg T; Niessner H; Meier F; Terheyden P; Königsrainer A; Garbe C; Flatz L; Pawelec G; Eigentler TK; Löffler MW; Weide B; Wistuba-Hamprecht K
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34933966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Yttrium-90 Induces an Effector Memory Response with Neoantigen Clonotype Expansion: Implications for Immunotherapy.
    Núñez K; Sandow T; Gimenez J; Hibino M; Cohen A; Thevenot P
    Cancer Res Commun; 2024 Aug; 4(8):2163-2173. PubMed ID: 39069671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peripheral Blood TCR Repertoire Profiling May Facilitate Patient Stratification for Immunotherapy against Melanoma.
    Hogan SA; Courtier A; Cheng PF; Jaberg-Bentele NF; Goldinger SM; Manuel M; Perez S; Plantier N; Mouret JF; Nguyen-Kim TDL; Raaijmakers MIG; Kvistborg P; Pasqual N; Haanen JBAG; Dummer R; Levesque MP
    Cancer Immunol Res; 2019 Jan; 7(1):77-85. PubMed ID: 30425105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T cell receptor sequencing of activated CD8 T cells in the blood identifies tumor-infiltrating clones that expand after PD-1 therapy and radiation in a melanoma patient.
    Wieland A; Kamphorst AO; Adsay NV; Masor JJ; Sarmiento J; Nasti TH; Darko S; Douek DC; Xue Y; Curran WJ; Lawson DH; Ahmed R
    Cancer Immunol Immunother; 2018 Nov; 67(11):1767-1776. PubMed ID: 30167863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.